Abstract
Drug therapy for human immunodeficiency virus (HIV) is highly effective in suppressing viral replication and restoring immune function in patients with HIV. However, this same treatment can also be associated with immunotoxicity. For example, zidovudine and various other antiretroviral agents are capable of causing bone marrow suppression. Agents used to treat opportunistic infections in these individuals, including ganciclovir, foscarnet, and sulfamethoxazoletrimethoprim, can cause additional hematotoxicity. Drug-drug interactions must also be considered and managed in order to control iatrogenic causes of immunotoxicity. In this review, we examine the normal immune response to HIV, and the benefits of antiretroviral therapy in prolonging immune function. We then discuss immune-related adverse effects of drugs used to treat HIV and the opportunistic infections that are common among these patients. Finally, we address in vitro, animal, and clinical evidence of toxicity associated with various combination use of these agents.
Keywords: Human immunodeficiency virus, acquired immunodeficiency syndrome, antiretrovirals, adverse drug reactions, drug interactions, bone marrow toxicity, zidovudine
Current Pharmaceutical Design
Title: Effects of Antiretroviral Therapy on Immunity in Patients Infected with HIV
Volume: 12 Issue: 9
Author(s): B. A. Garvy, D. J. Feola and A. C. Thornton
Affiliation:
Keywords: Human immunodeficiency virus, acquired immunodeficiency syndrome, antiretrovirals, adverse drug reactions, drug interactions, bone marrow toxicity, zidovudine
Abstract: Drug therapy for human immunodeficiency virus (HIV) is highly effective in suppressing viral replication and restoring immune function in patients with HIV. However, this same treatment can also be associated with immunotoxicity. For example, zidovudine and various other antiretroviral agents are capable of causing bone marrow suppression. Agents used to treat opportunistic infections in these individuals, including ganciclovir, foscarnet, and sulfamethoxazoletrimethoprim, can cause additional hematotoxicity. Drug-drug interactions must also be considered and managed in order to control iatrogenic causes of immunotoxicity. In this review, we examine the normal immune response to HIV, and the benefits of antiretroviral therapy in prolonging immune function. We then discuss immune-related adverse effects of drugs used to treat HIV and the opportunistic infections that are common among these patients. Finally, we address in vitro, animal, and clinical evidence of toxicity associated with various combination use of these agents.
Export Options
About this article
Cite this article as:
Garvy A. B., Feola J. D. and Thornton C. A., Effects of Antiretroviral Therapy on Immunity in Patients Infected with HIV, Current Pharmaceutical Design 2006; 12 (9) . https://dx.doi.org/10.2174/138161206776055886
DOI https://dx.doi.org/10.2174/138161206776055886 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma
Anti-Cancer Agents in Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Affinity Can have Many Faces: Thermodynamic and Kinetic Properties of Ras-Effector Complex Formation
Current Chemical Biology Insect Larvae: A New Platform to Produce Commercial Recombinant Proteins
Current Pharmaceutical Biotechnology Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials
Current Drug Targets Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Regulation of Gene Expression by Retinoids
Current Medicinal Chemistry Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA